Document is current
Any future updates will be listed below
-
Authors
Shoji, Kenji F https://orcid.org/0000-0002-8137-2521
Bayet, Elsa
Leverrier‐Penna, Sabrina https://orcid.org/0000-0002-6293-4760
Le Devedec, Dahiana
Mallavialle, Aude https://orcid.org/0000-0002-9380-6788
Marionneau‐Lambot, Séverine https://orcid.org/0000-0002-5041-8531
Rambow, Florian https://orcid.org/0000-0002-9727-8986
Perret, Raul
Joussaume, Aurélie
Viel, Roselyne
Fautrel, Alain https://orcid.org/0000-0002-3449-0779
Khammari, Amir https://orcid.org/0000-0001-9328-8004
Constantin, Bruno https://orcid.org/0000-0003-1668-581X
Tartare‐Deckert, Sophie https://orcid.org/0000-0001-8680-5720
Penna, Aubin https://orcid.org/0000-0002-1070-5990
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR‐12‐JSV2‐0004‐001)
Fondation ARC pour la Recherche sur le Cancer (PJA20151203419)
Ligue Contre le Cancer
Region Nouvelle Aquitaine (16/RALPC‐P‐R‐23)
Roche/Groupe Cancérologie Cutanée de la Société Française de Dermatologie
University of Rennes 1
- License Information
-
More Information
Article History
Received: 17 March 2022
Revised: 21 December 2022
Accepted: 10 January 2023
First Online: 6 February 2023
Disclosure and competing interests statement
: AP and KFS are involved in a patent protecting the use of TRPV2 as a biomarker and as a therapeutic target for melanoma (WO2017064159A1). All other authors declare that they have no competing interests or disclosures.
